Modalis Therapeutics Corporation (TYO:4883)

Market Cap	5.11B -26.3%
Revenue (ttm)	n/a
Net Income	-2.15B
EPS	-27.85
Shares Out	86.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,402,500
Average Volume	498,490
Open	58.00
Previous Close	57.00
Day's Range	57.00 - 61.00
52-Week Range	52.00 - 119.00
Beta	0.12
RSI	38.58
Earnings Date	Feb 12, 2026

About Modalis Therapeutics

Modalis Therapeutics Corporation engages in the research and development of therapeutics to treat patients with serious genetic disorders. The company is developing therapies for genetic diseases using its proprietary CRISPR-GNDM technology developed by Modalis that combines dCas9. It also develops various therapeutics for muscle disorders, cardiomyopathy, and CNS disorders. The company was formerly known as EdiGENE Corporation and changed its name to Modalis Therapeutics Corporation in August 2019. Modalis Therapeutics Corporation was incorpor...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 14
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4883